Clinical trials: Insufficient Metabolic Control
Diabetes Mellitus, Type 2
Effect of PF-00734200 in Subjects With Type 2 Diabetes
To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin
- Trial name
- NCT00618007
- Testing
- PF-00734200 30 mg QD, PF-00734200 20 mg QD
- Where
- 79 sites in United States, Canada and 2 more
- Volunteers
- 289 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (5 mg once daily) compared to placebo given for 24 weeks as add on therapy to metformin in combination with pioglitazone in…
- Trial name
- NCT00996658
- Testing
- Linagliptin
- Where
- 52 sites in United States, France and 2 more
- Volunteers
- 278 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, End-Stage Kidney Disease
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.
- Trial name
- NCT00509236
- Testing
- Sitagliptin, Glipizide
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)
The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00087516
- Testing
- Sitagliptin (MK0431), Sitagliptin, Metformin - Rescue
- Volunteers
- 741 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
The primary objective is to demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (Hb1Ac) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic…
- Trial name
- SOTA-BONE (NCT03386344)
- Testing
- Sotagliflozin
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 376 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 304 (NCT05504239)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Handok Inc.
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the…
- Trial name
- NCT02419612
- Testing
- Saxagliptin, Dapagliflozin, Glimepiride
- Where
- 84 sites in United States, Czechia and 8 more
- Volunteers
- 444 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and metformin in patients with diabetes mellitus.
- Trial name
- NCT01135433
- Testing
- ipragliflozin, metformin
- Where
- 7 sites in Japan
- Volunteers
- 168 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus
PPAR - Combination With Metformin
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic…
- Trial name
- NCT00162240
- Testing
- Muraglitazar
- Where
- 203 sites in United States, Argentina and 10 more
- Volunteers
- 534 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
The Practical Evidence of Antidiabetic Combination Therapy in Korea
This study evaluate the efficacy and safety of alogliptin and pioglitazone combination therapy in comparison with either alogliptin or pioglitazone on glucose control in the metformin-treated type 2 diabetic patients in Korea.
- Trial name
- PEAK (NCT02231021)
- Testing
- alogliptin, Pioglitazone, alogliptin + pioglitazone
- Where
- South Korea
- Volunteers
- 216 people
- Sponsor
- Kun-Ho Yoon
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with…
- Trial name
- NCT04255238
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg
- Volunteers
- 468 people
- Sponsor
- LG Chem
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Primary Objective: To demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on diet and…
- Trial name
- NCT02926937
- Testing
- Sotagliflozin (SAR439954)
- Where
- 70 sites in United States, Canada and 1 more
- Volunteers
- 399 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.
- Trial name
- NCT01257412
- Testing
- Dapagliflozin
- Where
- 15 sites in India
- Volunteers
- 375 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more…
- Trial name
- REVITALIZE 1 (NCT04419779)
- Testing
- Duodenal Mucosal Resurfacing (DMR)
- Where
- 58 sites in United States, Belgium and 5 more
- Volunteers
- 320 people
- Sponsor
- Fractyl Health Inc.
Type 1 Diabetes Mellitus
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1…
- Trial name
- NCT02500979
- Testing
- Pramlintide acetate, Lispro insulin U-100, Regular insulin U-100
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca